" "
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Primers Provide Significant Breakthrough in Assay Sensitivity

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Swift Biosciences, Inc. has announced a new addition to its line of myT® Primer reagents for the detection of key cancer mutations.

myT BRAF-Ultra, an ultrasensitive version of myT BRAF, provides 0.01% sensitivity down to single copy detection of BRAF mutations and is now available from Swift.  myT BRAF-Ultra can detect less than 10 copies of mutant BRAF V600E/K with very low breakthrough amplification from a background of 10,000 Swift-myT-BRAF-Press-Releas.gifwild-type genomic DNA copies. While myT BRAF-Ultra works well with fresh frozen and FFPE samples, this level of sensitivity also makes the product ideal for use when the sample material is limiting or where the target is present at very low concentration, such as with circulating tumor cells (CTCs), serum, plasma and needle biopsies. Each myT BRAF-Ultra package includes sufficient reagents to assess up to 14 samples when run in triplicate, plus a positive and a negative control.

myT BRAF-Ultra is the newest addition to the myT Primer line of products.  The first product in the family, myT BRAF, can detect 1% mutant BRAF V600E/K present in a background of 1,000 wild-type genomic DNA copies with no breakthrough amplification from wild-type, resulting in assays that give definitive Yes/No answers over a wide dynamic range and reduce or completely eliminate the need for delta Ct methods to call results.  Each myT BRAF package includes sufficient reagents to assess up to 28 samples plus a positive and a negative control.

The extreme selectivity and reproducibility of myT Primers provides an increased level of confidence and convenience in qPCR assays and makes them ideal for use when the sample material is limiting or where the target is present at very low concentration.  Additional myT Primer reagents will be coming soon, including primers for high sensitivity detection of KRAS mutations in codons 12 and 13.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
The Spice of Life
Scientists discover important genetic source of human diversity.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH-funded study could lead to new tick control methods.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!